Marshall Fordyce, PRESIDENT AND CEO at Vera Therapeutics, Inc. (VERA), sold 38,276 shares at $27.89 ($1.1M) on 2025-02-21, disclosed to the SEC on 2025-02-27.
Scheduled sale ($1.1M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.89 | 10,613 | $296K | 27.9% |
| 2 | $27.89 | 10,613 | $296K | 27.9% |
| 3 | $27.55 | 7,975 | $220K | 20.7% |
| 4 | $27.55 | 7,975 | $220K | 20.7% |
| 5 | $28.32 | 1,100 | $31K | 2.9% |
| Total | $27.76 avg | 38,276 |
| $1.1M |
| 100% |
| Filing → |
| VERA | SELL | 2026-07-09 | $2.0M | — | Filing → |
| VERA | SELL | 2026-06-24 | $702K | — | Filing → |
| VERA | SELL | 2026-05-13 | $680K | — | Filing → |